# DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award

Source: https://welltoldgrants.com/grants/ht942524alsrppcta-dod-amyotrophic-lateral-sclerosis-pilot-clinical-trial-award/  
Official notice: https://www.grants.gov/search-results-detail/353161

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 3 awards worth $8.0 million in total. Applications closed on July 10, 2024.

| Field | Value |
|---|---|
| Opportunity number | HT942524ALSRPPCTA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | July 10, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 3 |
| Total funding | $8.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The FY24 ALSRP Pilot Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ALS. Projects may range from phase 1 to small-scale phase 2 trials and should aim to de-risk and inform the design of more advanced trials by investigating safety, feasibility, biomarker application, and therapeutic efficacy in relevant patient populations. Clinical trials may be designed to evaluate promising drugs, biologics, or devices with anticipated therapeutic impact that is supported by strong scientific rationale and existing preliminary studies and/or preclinical data. Clinical trials aimed to improve aspects of patient care and ALS symptom management are also applicable to this award mechanism. Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more study participants are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY24 ALSRP program announcements being offered. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. Applicants must clearly describe a biomarker-driven approach and its potential to de-risk and improve the design of anticipated later-stage trials. For further description, see Attachment 13, Biomarker Statement. Biomarker development and characterization can include target engagement biomarkers, pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, and/or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup.

## Questions people ask

### Is HT942524ALSRPPCTA still open?

No. It closed on July 10, 2024. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award?

Closed July 10, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $8.0 million in total across about 3 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.